Rocket Pharmaceuticals, Inc. (RCKT) ... will be automatically converted on a 4.05783-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}} 'Management is led by founder and Chief Executive Officer John Valliant, Ph.D., who was previously CEO at the Centre for Probe Development and Commercialization, which he also founded.Below is a brief overview video of the firm's TAT approach:The firm's sole drug candidate, FPI-1434, is in Phase 1 monotherapy safety trials and seeks to deliver alpha particle payloads to solid tumors expressing IGF-1R (Insulin-like Growth Factor - 1 Receptor).Below is the current status of the company’s drug development pipeline:Investors in the firm have invested at least $103.4 million and include HealthCap, Varian Medical Systems (VAR), Johnson This represents a forecast CAGR (Compound Annual Growth Rate) of 15.0% from 2019 to 2027.Key elements driving this expected growth are a rising prevalence of breast cancer and lung cancer worldwide as well as increasing reimbursement policies and significant development activities by biopharmaceutical firms.Major competitive vendors that provide or are developing treatments include:Fusion’s recent financial results are typical of a clinical stage biopharma in that they feature no revenue and significant RBelow are the company’s financial results for the past two and ¼ years (audited PCAOB for full years):As of March 31, 2020, the company had $67.4 million in cash and $16.8 million in total liabilities (unaudited, interim).FUSN intends to sell 8.35 million shares of common stock at a midpoint price of $15.00 per share for gross proceeds of approximately $125.0 million, not including the sale of customary underwriter options.No existing shareholders have indicated an interest to purchase shares at the IPO price, a potentially negative signal of the lack of investor support for the IPO.Assuming a successful IPO at the midpoint of the proposed price range, the company’s enterprise value at IPO would approximate $562.7 million.Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximatelyPer the firm’s most recent regulatory filing, it plans to use the net proceeds ‘to fund the development FPI-1434 as a monotherapy, to advance the development of combination therapies of FPI-1434 with checkpoint inhibitors and DDRIs, including PARP inhibitors, to advance FPI-1966, to further develop and expand our clinical pipeline and for ongoing research and development activities and to fund working capital and other general corporate activities.’Management’s presentation of the company roadshow is Listed underwriters of the IPO are Morgan Stanley, Jefferies, Cowen and Wedbush PacGrow.Fusion is seeking a larger than usual IPO amount to fund its program development.Recently, I’ve seen more life science IPOs seek $125 million in new capital, whereas in previous periods the typical norm was around $75 million.For its lead program, the firm has recently entered Phase 1 safety trials and expects initial topline data in 3 - 6 months.The market opportunity for treating solid tumors is enormous, possibly the largest single market within the cancer space, on a global basis.Management has disclosed no collaborations, although its in-licensed antibody from Immunogen had been developed in conjunction with Sanofi, although it ‘failed to demonstrate sufficient positive therapeutic efficacy’ in those trials.Morgan Stanley is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 66.8% since their IPO. Market Events nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? Find the latest Earnings Report Date for Rocket Pharmaceuticals, Inc. Common Stock (RCKT) at Nasdaq.com. Click IPO Securities, LLC is a broker dealer registered with the SEC, and is a member of FINRA and SIPC.Click IPO Holdings, LLC, owner of the proprietary technology application known as ClickIPO TM is the parent company of Click IPO Securities, LLC.
Analyst Activity 1,511 people own Rocket Pharmaceuticals on Robinhood on July 30, 2020. It is possible that this date will be updated in the future, once the company announces the actual date.
